Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

被引:110
作者
Abdel-Wahab, N. [1 ,2 ]
Talathi, S. [3 ]
Lopez-Olivo, M. A. [1 ]
Suarez-Almazor, M. E. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Sect Rheumatol & Clin Immunol, Houston, TX 77030 USA
[2] Assiut Univ Hosp, Rheumatol & Rehabil Dept, Fac Med, Assiut, Egypt
[3] Weill Cornell Med Coll, Lincoln Med Ctr, Bronx, NY USA
关键词
Antiphospholipid syndrome; infection; anticardiolipin antibodies; thromboembolic events; observational studies; meta-analysis; systematic review; HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; PARVOVIRUS B19 INFECTION; CHRONIC LIVER-DISEASE; ANTICARDIOLIPIN ANTIBODIES; HIV-INFECTION; CLINICAL-SIGNIFICANCE; HIGH PREVALENCE; LUPUS ANTICOAGULANT; AUTOIMMUNE-DISEASE;
D O I
10.1177/0961203317731532
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection. Method We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included. Results We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6-19.4), as were those with HCV (RR 6.3, 95% CI 3.9-10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8-9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4-22.2). The only statistically significant increased risk for anti-2-glycoprotein I (anti-2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0-22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3-2.6), and those with EBV, elevated anti-2-GPI antibodies (RR 2.2, 95% CI 1.3-3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0-18.1), and HBV (5.9%, 95% CI 2.0-11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78-45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL. Conclusions Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information.
引用
收藏
页码:572 / 583
页数:12
相关论文
共 107 条
[1]
Systematic review of case reports of antiphospholipid syndrome following infection [J].
Abdel-Wahab, N. ;
Lopez-Olivo, M. A. ;
Pinto-Patarroyo, G. P. ;
Suarez-Almazor, M. E. .
LUPUS, 2016, 25 (14) :1520-1531
[2]
Abuaf N, 1997, THROMB HAEMOSTASIS, V77, P856
[3]
ADEBAJO AO, 1993, CLIN EXP IMMUNOL, V92, P73, DOI 10.1111/j.1365-2249.1993.tb05950.x
[4]
ADEBAJO AO, 1992, BRIT J RHEUMATOL, V31, P45
[5]
Agarwal N, 2001, INDIAN J MED RES, V113, P170
[6]
Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus [J].
Alessandri, C ;
Bombardieri, M ;
Di Prospero, L ;
Conigliaro, P ;
Conti, F ;
Labbadia, G ;
Misasi, R ;
Sorice, M ;
Valesini, G .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 140 (01) :173-180
[7]
Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis [J].
Ambrosino, Pasquale ;
Lupoli, Roberta ;
Tarantino, Paolo ;
Di Minno, Alessandro ;
Tarantino, Luciano ;
Di Minno, Matteo Nicola Dario .
DIGESTIVE AND LIVER DISEASE, 2015, 47 (06) :478-487
[8]
[Anonymous], Stata Statistical Software
[9]
Antiphospholipid antibodies in Brazilian hepatitis C virus carriers [J].
Atta, A. M. ;
Estevam, P. ;
Parana, R. ;
Pereira, C. M. ;
Leite, B. C. O. ;
Sousa-Atta, M. L. B. .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2008, 41 (06) :489-492
[10]
BARRILE A, 1992, Recenti Progressi in Medicina, V83, P350